Latest Issue

Pulmonary & Nasal Drug Delivery180

Issue No #180 Nov 2025 November 22nd, 2025

Issue 180 - Nov 2025

Inside the magazine

CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT

Catalent Pharma Solutions

CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT

Carolyn Berg and Dr Alan Watts examine strategy considerations that can help emerging biotech companies navigate early-stage pulmonary drug development, providing practical guidance for addressing challenges of respiratory delivery and avoiding common pitfalls that can derail development programmes.

Interview: Aptar Pharma Expansion With New R&D Center

Christophe Pierre

Interview: Aptar Pharma Expansion With New R&D Center

In this interview, Christophe Pierre introduces Aptar Pharma’s new R&D Center in France, and outlines how the new facility will assist the development of smarter, more integrated drug delivery solutions, facilitating progression from concept to full-scale industrialisation across multiple therapeutic fields.

RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?

RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?

Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.

STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER

Dr Yannick Baschung

STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER

Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.

DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL

DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL

As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.

INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES

Dr Philippe Rogueda

INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES

Dr Philippe Rogueda discusses the therapeutic potential promised by oligonucleotides and presents the case for prioritising the inhalation route as the ideal delivery mechanism for these drugs, highlighting how direct delivery to the lungs via devices such as dry power inhalers or soft mist inhalers can maximise the therapeutic efficacy and minimise the side effects of these exciting drugs.

HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES

Dr Peter Harley

HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES

Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.

DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE

DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE

Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.

CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY

Dr Keat Theng Chow

CLEARING THE AIR(WAY): DEBUNKING THREE COMMON MYTHS ABOUT INHALED DRUG DELIVERY

Dr Keat Theng Chow and Susana Ecenarro explore three myths surrounding inhalation as a route of administration, clearing the way for a deeper understanding of one of pharma’s most exciting areas for innovation.

FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING

Matthias Müller

FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING

Matthias Müller details how a close collaboration between Contexo and a pharmaceutical manufacturer led to the rapid development of a novel nasal spray product, taking the project from prototyping to market within 14 months, shaving 10 months off the anticipated launch date.

Interview: Integrating Phillips Medisize and Vectura’s Operations

Charlie Schumacher

Phillips Medisize

Interview: Integrating Phillips Medisize and Vectura’s Operations

In this interview, Charlie Schumacher and Sandy Munro discuss Phillips Medisize’s progress on its integration of Vectura, covering aspects such as cultural alignment, technical innovation and the evolving role of CDMOs in the inhalation landscape.

ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET

INDUSTRIALISATION

Parker O-Ring & Engineered Seals Division

ADVANCING ELASTOMER SEAL SOLUTIONS FOR THE PRESSURISED METERED DOSE INHALER MARKET

Nathan Sowder discusses Parker O-Ring & Engineered Seals Division’s role and history in providing advanced elastomer seals and components to the drug delivery industry, with a particular emphasis on pressurised metered dose inhalers.

FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT

FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT

Ross Errington introduces Bespak’s Holmes Chapel (UK) site, which is equipped to support device development programmes from early-stage formulation to large-scale manufacture.

ORBITAL: A NOVEL HIGH-PAYLOAD, MULTI-BREATH DPI POISED FOR CLINICAL ADVANCEMENT

ORBITAL: A NOVEL HIGH-PAYLOAD, MULTI-BREATH DPI POISED FOR CLINICAL ADVANCEMENT

David Farrow, Jonathan Mulpas and Solange Le Nuz discuss the patient-centric and data-driven development of Aptar Pharma’s Orbital dry powder inhaler platform, tracing its evolution from an initial concept to a clinically-ready device.

NAVIGATING THE REGULATORY PATHWAY FOR NEXT-GENERATION NEBULISERS IN COMBINATION WITH BIOLOGICS

Edgar Hernan Cuevas Brun

HCmed Innovations

NAVIGATING THE REGULATORY PATHWAY FOR NEXT-GENERATION NEBULISERS IN COMBINATION WITH BIOLOGICS

Edgar Hernan Cuevas Brun discusses the role of nebulisers in delivering larger doses of fragile biologics, delving into the global regulatory landscape that must be understood in order to deliver these drugs on the market.

ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY

Dr Nicolas Buchmann

ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY

Dr Nicolas Buchmann and Bernhard Müllinger, discuss the capabilities of soft mist inhalers in terms of usability for patients, sustainability, compatibility with biologics and cost-effective delivery, showcasing these advantages in Resyca’s Pre-Filled Syringe Inhaler (PFSI).

EXPANDING OPPORTUNITIES FOR INHALED DRUG DELIVERY

Dr Gunilla Petersson

EXPANDING OPPORTUNITIES FOR INHALED DRUG DELIVERY

Dr Gunilla Petersson considers the challenges associated with efficiently delivering drugs to the lungs and the potential of nanoparticle-based formulations to achieve high lung deposition of small molecules and biologics, using gentle particle processing techniques that enable the delivery of sensitive drugs.

Top